Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 10:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 675 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Active Chronic Graft Versus Host Disease Clear all
Completed Phase 1 Interventional

A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B

NCT01671787
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
GS-7340, Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
San Diego, California • Baltimore, Maryland • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 10, 2026, 10:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children

NCT01091246
View directory record Official record
Conditions
Healthy or Stable Chronic Illness
Interventions
Q/LAIV (MEDI3250), FluMist/B/Yamagata, FluMist/B/Victoria
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
2,312 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
110
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 10, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia

NCT00514696
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
GCS-100
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Denver, Colorado • Winter Park, Florida • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 10, 2026, 10:46 AM EDT
Terminated Phase 1 Interventional

Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma

NCT00383097
View directory record Official record
Conditions
Hodgkins Lymphoma, Non-Hodgkin Lymphoma
Interventions
LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES, LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 10, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

NCT01740791
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
Velpatasvir, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Costa Mesa, California • DeLand, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 10, 2026, 10:46 AM EDT
Suspended Phase 1 Interventional

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

NCT06677710
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis, Non-Active SPMS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases, Demyelinating Diseases, Immune System Diseases, Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
Interventions
IDP-023, Ocrelizumab, Interleukin-2, Cyclophosphamide, Fludarabine, Mesna
Drug
Lead sponsor
Indapta Therapeutics, INC.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 10, 2026, 10:46 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the Knee

NCT02847702
View directory record Official record
Conditions
Osteoarthritis Pain of the Knee
Interventions
VM902A 200-mg Capsules, VM902A 400-mg Capsules, Naproxen 500-mg Capsules, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
31
States / cities
Birmingham, Alabama • Huntsville, Alabama • DeLand, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 10, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Telehealth Virtual Reality Gaming on Cardiometabolic Health Among Youth With Cerebral Palsy

NCT05336227
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Virtual Reality Exergaming
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
13 Years to 24 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 10, 2026, 10:46 AM EDT
Completed Not applicable Interventional Results available

Impact of Exercise Training on Pain and Brain Function in Gulf War Veterans

NCT01350492
View directory record Official record
Conditions
Chronic Musculoskeletal Pain
Interventions
Resistance Exercise Training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 10, 2026, 10:46 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Chronic Pain, Couples, & Physical Activity

NCT04077164
View directory record Official record
Conditions
Chronic Pain, Fibromyalgia, Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis, Ankylosing Spondylitis, Rheumatoid Arthritis, Chronic Low-back Pain, Chronic Shoulder Pain
Interventions
No intervention, observational only.
Other
Lead sponsor
Illinois Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 10, 2026, 10:46 AM EDT
Completed Not applicable Interventional

Open Pilot Trial of a Mind-Body Intervention for Patients With Chronic Hip Pain

NCT06820242
View directory record Official record
Conditions
Hip Pain, Hip Pain Chronic, Mind-Body Therapies
Interventions
HIPS
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 10, 2026, 10:46 AM EDT
Completed Not applicable Interventional

Improving Function, Participation and Function After Acute Hospitalization in Older Adults

NCT01872637
View directory record Official record
Conditions
Frail Older Adults
Interventions
Progressive Multi-Component Intervention, Usual Care
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Aurora, Colorado • Glenside, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 10, 2026, 10:46 AM EDT
Completed Phase 4 Interventional Results available

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

NCT02970669
View directory record Official record
Conditions
Heart Failure, Reduced Ejection Fraction
Interventions
sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 10, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

NCT00887588
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
LCZ696, Valsartan, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Little Rock, Arkansas • Chicago, Illinois • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 10, 2026, 10:46 AM EDT
Terminated Phase 3 Interventional Results available

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease

NCT01155388
View directory record Official record
Conditions
Iron Deficiency Anemia, Nondialysis-dependent Chronic Kidney Disease
Interventions
Ferumoxytol, Oral Iron
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 10, 2026, 10:46 AM EDT
Completed Not applicable Interventional

Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program

NCT00792454
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Kidney Disease, Cardiovascular Disease
Interventions
exercise training
Behavioral
Lead sponsor
MaineHealth
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 10, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

NCT03982186
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
JNJ-73763989, Placebo for JNJ-73763989, JNJ-56136379, Placebo for JNJ-56136379, Nucleos(t)ide Analog (NA)
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
18 Years to 65 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Bakersfield, California • Los Angeles, California • San Clemente, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 10, 2026, 10:46 AM EDT
Completed Not applicable Interventional Results available

Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy

NCT00405275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, methotrexate, Sulfasalazine, Hydroxychloroquine, Placebo, triple, Placebo, etanercept
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
28
States / cities
Loma Linda, California • Long Beach, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Oct 10, 2026, 10:46 AM EDT
Completed Not applicable Interventional Results available

Pain Program for Active Coping & Training

NCT02113592
View directory record Official record
Conditions
Chronic Non-malignant Pain
Interventions
Interdisciplinary pain program
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia • Honolulu, Hawaii • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 10, 2026, 10:46 AM EDT
Completed Phase 4 Interventional Results available

Placebo In Chronic Back Pain (Phase 2)

NCT02986334
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Naproxen, Omeprazole, Placebo
Drug
Lead sponsor
Apkar Apkarian
Other
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 10, 2026, 10:46 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

NCT02629692
View directory record Official record
Conditions
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
Interventions
Vodobatinib (K0706) capsules
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
8
States / cities
Downey, California • Los Angeles, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 10, 2026, 10:46 AM EDT
Completed Phase 4 Interventional

Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients

NCT03611699
View directory record Official record
Conditions
COPD
Interventions
Umeclidinium / Vilanterol Dry Powder Inhaler, Placebo
Drug
Lead sponsor
Gary L. Pierce
Other
Eligibility
30 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 10, 2026, 10:46 AM EDT
Withdrawn No phase listed Observational

Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients

NCT01809730
View directory record Official record
Conditions
Coronary Artery Disease, Cerebral Vascular Disease, Peripheral Artery Disease, Renal Insufficiency, Diabetes, COPD, Hypertension, Active Smoker, Cancer, CHF, Prior DVT/PE
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 10, 2026, 10:46 AM EDT
Active, not recruiting No phase listed Observational

HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B

NCT01796457
View directory record Official record
Conditions
Hepatitis B
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
7
States / cities
San Francisco, California • Boston, Massachusetts • Plymouth, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 10, 2026, 10:46 AM EDT